PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15363995-7 2004 Pretreatment (15 min, s.c.) with the vasopressin V1 receptor antagonist Mca1,Tyr(Me)2AVP (the Manning peptide; 0.02-0.2 microg kg(-1)) or the platelet-activating factor receptor antagonist ginkgolide B (BN 52021; 0.25-2.5 mg kg(-1)) alone caused a dose-dependent reduction of the ST-segment depression. Tyrosine 77-80 arginine vasopressin Rattus norvegicus 37-48 11832328-4 2002 AVP also stimulates the tyrosine phosphorylation of the nonreceptor tyrosine kinase proline-rich tyrosine kinase 2 (Pyk2) and promotes Src family kinase phosphorylation at Tyr(418), indicative of Src activation. Tyrosine 24-32 arginine vasopressin Rattus norvegicus 0-3 12072585-10 2002 AVP significantly increased tyrosine phosphorylation in VSMCs, with enhanced effects in SHR compared with WKY (p < 0.05). Tyrosine 28-36 arginine vasopressin Rattus norvegicus 0-3 12763250-13 2003 Under the same conditions of stress, the infusion of 15 microgram/day of the vasopressin V1a/1b receptor antagonist [dP Tyr (Me)(2)AVP] significantly increased MR and GR binding in hippocampus and anterior pituitary; 5 microgram/day significantly decreased pituitary MR binding. Tyrosine 120-123 arginine vasopressin Rattus norvegicus 77-88 11832328-4 2002 AVP also stimulates the tyrosine phosphorylation of the nonreceptor tyrosine kinase proline-rich tyrosine kinase 2 (Pyk2) and promotes Src family kinase phosphorylation at Tyr(418), indicative of Src activation. Tyrosine 172-175 arginine vasopressin Rattus norvegicus 0-3 11208575-3 2001 Treatment with the vasopressin pressor (V(1)) receptor antagonist [d(CH(2))(5)Tyr(Me)-AVP] before ethanol administration significantly reduced the ACTH and corticosterone level increases. Tyrosine 78-81 arginine vasopressin Rattus norvegicus 86-89 10409128-4 1999 d(CH(2))(5)[Tyr(Me)(2)]AVP (10 nM), a V(1a) receptor antagonist, and L-366,948 (10 nM), a highly specific OT-receptor antagonist, failed to inhibit AVP-induced glucagon release. Tyrosine 12-15 arginine vasopressin Rattus norvegicus 23-26 10549862-1 1999 To extend the utility of a renal targeting system using carbohydrate derivatives, we investigated the in vivo tissue distribution in rats of arginine-vasopressin (AVP) derivatives modified at the phenolic hydroxy group of tyrosine by linking it to some sugars, namely D-glucose, D-galactose, D-mannose and L-fucose, via an octamethylene group. Tyrosine 222-230 arginine vasopressin Rattus norvegicus 163-166 10462367-3 1999 In addition, concentration-response curves to vasopressin with incubation of a vasopressin V(1) receptor antagonist d(CH(2))(5)Tyr(Me) arginine vasopressin and concentration-response curves to a V(2) receptor agonist 1-desamino-8-D-arginine vasopressin were performed. Tyrosine 127-130 arginine vasopressin Rattus norvegicus 46-57 10462367-3 1999 In addition, concentration-response curves to vasopressin with incubation of a vasopressin V(1) receptor antagonist d(CH(2))(5)Tyr(Me) arginine vasopressin and concentration-response curves to a V(2) receptor agonist 1-desamino-8-D-arginine vasopressin were performed. Tyrosine 127-130 arginine vasopressin Rattus norvegicus 79-90 10462367-3 1999 In addition, concentration-response curves to vasopressin with incubation of a vasopressin V(1) receptor antagonist d(CH(2))(5)Tyr(Me) arginine vasopressin and concentration-response curves to a V(2) receptor agonist 1-desamino-8-D-arginine vasopressin were performed. Tyrosine 127-130 arginine vasopressin Rattus norvegicus 79-90 10462367-3 1999 In addition, concentration-response curves to vasopressin with incubation of a vasopressin V(1) receptor antagonist d(CH(2))(5)Tyr(Me) arginine vasopressin and concentration-response curves to a V(2) receptor agonist 1-desamino-8-D-arginine vasopressin were performed. Tyrosine 127-130 arginine vasopressin Rattus norvegicus 79-90 8724995-0 1996 Arginine vasopressin reduces the blood-brain transfer of L-tyrosine and L-valine: further evidence of the effect of the peptide on the L-system transporter at the blood-brain barrier. Tyrosine 57-67 arginine vasopressin Rattus norvegicus 9-20 9810690-1 1998 Arginine-vasopressin (AVP) was acylated with various acyl azides (2a-j) in pH 9.1 buffer to give AVP derivatives (11a-j) modified at the tyrosine side chain with a carbohydrate via a spacer arm. Tyrosine 137-145 arginine vasopressin Rattus norvegicus 0-20 9810690-1 1998 Arginine-vasopressin (AVP) was acylated with various acyl azides (2a-j) in pH 9.1 buffer to give AVP derivatives (11a-j) modified at the tyrosine side chain with a carbohydrate via a spacer arm. Tyrosine 137-145 arginine vasopressin Rattus norvegicus 22-25 9810690-1 1998 Arginine-vasopressin (AVP) was acylated with various acyl azides (2a-j) in pH 9.1 buffer to give AVP derivatives (11a-j) modified at the tyrosine side chain with a carbohydrate via a spacer arm. Tyrosine 137-145 arginine vasopressin Rattus norvegicus 97-100 9328942-4 1997 The addition of the V1-receptor antagonist [(d (CH2)5, Tyr (Et)2) arginine vasopressin] (10(-5) M) to luminal perfusion blocked luminal AVP mediated stimulation in ED and LD segments. Tyrosine 55-58 arginine vasopressin Rattus norvegicus 75-86 10562440-0 1999 Vasopressin stimulates tyrosine phosphorylation by activation of PKC in the rat smooth muscle cell line, A-10. Tyrosine 23-31 arginine vasopressin Rattus norvegicus 0-11 10562440-1 1999 Arginine vasopressin (AVP)-induced tyrosine phosphorylation was studied in a rat smooth muscle cell line, A-10, by western blotting, using a monoclonal antibody against phosphotyrosine. Tyrosine 35-43 arginine vasopressin Rattus norvegicus 9-20 28976665-5 1998 Moreover, pretreatment with the vasopressin pressor-receptor antagonist, d(CH2 )5 Tyr(Me)AVP (0.01-0.2mg/kg, s.c.) dose-dependently attenuated such damage. Tyrosine 82-85 arginine vasopressin Rattus norvegicus 32-43 8611034-12 1996 When cells were preincubated in 10 mM vanadate, a tyrosine phosphatase inhibitor, AVP induced a transient increase in tyrosine phosphorylation (5-60 s). Tyrosine 50-58 arginine vasopressin Rattus norvegicus 82-85 8611034-15 1996 Genistein blocked tyrosine phosphorylation induced by AVP and vanadate, and it blocked the increase in [Ca2+]i induced by vanadate alone. Tyrosine 18-26 arginine vasopressin Rattus norvegicus 54-57 8611034-16 1996 In contrast, lavendustin or tyrphostin unexpectedly enhanced tyrosine phosphorylation induced by vanadate alone and precluded assessment of AVP-induced tyrosine phosphorylation in the presence of vanadate. Tyrosine 152-160 arginine vasopressin Rattus norvegicus 140-143 8611034-19 1996 Under conditions where changes in phosphorylation could be measured, the results suggested that AVP-activated increases in tyrosine phosphorylation may be coupled to AVP-activated mechanisms that regulate influx of extracellular Ca2+ and release of intracellular Ca2+. Tyrosine 123-131 arginine vasopressin Rattus norvegicus 96-99 8611034-19 1996 Under conditions where changes in phosphorylation could be measured, the results suggested that AVP-activated increases in tyrosine phosphorylation may be coupled to AVP-activated mechanisms that regulate influx of extracellular Ca2+ and release of intracellular Ca2+. Tyrosine 123-131 arginine vasopressin Rattus norvegicus 166-169 8115425-4 1994 ICV pretreatment with a V1 vasopressin receptor antagonist, d(CH2)5[Tyr(Me)2]AVP, prevented barrel rotation, while similar treatment with a V2-antagonist, d(CH2)5[dIle2Ile4]AVP, did not affect vasopressin-induced barrel rotation. Tyrosine 68-71 arginine vasopressin Rattus norvegicus 27-38 8572202-3 1995 The antagonist with potent V1b receptor-blocking activity, dP[Tyr(Me)2]AVP (10(-7) M), abolished the effect of OT and AVP, whereas the highly selective OT receptor antagonist L-366,948 (10(-6) M) did not change the effect of OT, nor did a V1a receptor antagonist, d(CH2)5[Tyr(Me)2]AVP (10(-7) M), change the effect of AVP. Tyrosine 62-65 arginine vasopressin Rattus norvegicus 71-74 8572202-3 1995 The antagonist with potent V1b receptor-blocking activity, dP[Tyr(Me)2]AVP (10(-7) M), abolished the effect of OT and AVP, whereas the highly selective OT receptor antagonist L-366,948 (10(-6) M) did not change the effect of OT, nor did a V1a receptor antagonist, d(CH2)5[Tyr(Me)2]AVP (10(-7) M), change the effect of AVP. Tyrosine 62-65 arginine vasopressin Rattus norvegicus 118-121 8572202-3 1995 The antagonist with potent V1b receptor-blocking activity, dP[Tyr(Me)2]AVP (10(-7) M), abolished the effect of OT and AVP, whereas the highly selective OT receptor antagonist L-366,948 (10(-6) M) did not change the effect of OT, nor did a V1a receptor antagonist, d(CH2)5[Tyr(Me)2]AVP (10(-7) M), change the effect of AVP. Tyrosine 62-65 arginine vasopressin Rattus norvegicus 118-121 8572202-3 1995 The antagonist with potent V1b receptor-blocking activity, dP[Tyr(Me)2]AVP (10(-7) M), abolished the effect of OT and AVP, whereas the highly selective OT receptor antagonist L-366,948 (10(-6) M) did not change the effect of OT, nor did a V1a receptor antagonist, d(CH2)5[Tyr(Me)2]AVP (10(-7) M), change the effect of AVP. Tyrosine 62-65 arginine vasopressin Rattus norvegicus 118-121 8572202-7 1995 d[D-3-Pal]VP, a V1b receptor agonist, increased insulin release dose dependently (10(-9) to 10(-6) M), and this effect was antagonized by dP[Tyr(Me)2]AVP but not by WK-3-6 (10(-6) M). Tyrosine 141-144 arginine vasopressin Rattus norvegicus 150-153 8553914-0 1995 The effect of vasopressin analogue [d(CH2)5(1),Tyr(Me)2]AVP on memory process in rats with experimental amnesia. Tyrosine 47-50 arginine vasopressin Rattus norvegicus 14-25 8553914-1 1995 We investigated the effect of a single 2 micrograms dose of vasopressin (AVP) analogue [(CH2)5(1),Tyr(Me)2]AVP on the processes of retrieval of conditioned reflexes in rats with experimentally induced amnesia. Tyrosine 98-101 arginine vasopressin Rattus norvegicus 60-71 7681349-12 1993 Bilateral microinjections of an AVP antagonist, d(CH2)5[Tyr(Me)2]AVP into the nRVL produced no change in AP but blocked the increase produced by subsequent injections of AVP. Tyrosine 56-59 arginine vasopressin Rattus norvegicus 32-35 8387499-3 1993 In this paper direct evidence is presented for tyrosine and threonine phosphorylation of MAP kinase in concert with elevated activity in response to vasopressin in primary cultures of vascular smooth muscle cells. Tyrosine 47-55 arginine vasopressin Rattus norvegicus 149-160 7681349-12 1993 Bilateral microinjections of an AVP antagonist, d(CH2)5[Tyr(Me)2]AVP into the nRVL produced no change in AP but blocked the increase produced by subsequent injections of AVP. Tyrosine 56-59 arginine vasopressin Rattus norvegicus 65-68 7681349-12 1993 Bilateral microinjections of an AVP antagonist, d(CH2)5[Tyr(Me)2]AVP into the nRVL produced no change in AP but blocked the increase produced by subsequent injections of AVP. Tyrosine 56-59 arginine vasopressin Rattus norvegicus 65-68 1706722-0 1991 Endothelin, vasopressin, and angiotensin II enhance tyrosine phosphorylation by protein kinase C-dependent and -independent pathways in glomerular mesangial cells. Tyrosine 52-60 arginine vasopressin Rattus norvegicus 12-23 1579218-10 1992 In the presence of the vasopressin V1-receptor antagonist, d(CH2)5[Tyr(Et)]DAVP, the pressor and heart rate responses to noradrenaline injected into the paraventricular nuclei were abolished, as were the vasoconstrictions in the renal, superior mesenteric and hindquarter vascular beds. Tyrosine 67-70 arginine vasopressin Rattus norvegicus 23-34 1548476-6 1992 Also, the levels of tyrosine and phenylalanine increased 15% and 35%, respectively, during administration of vasopressin. Tyrosine 20-28 arginine vasopressin Rattus norvegicus 109-120 1838582-3 1991 AVP administration caused a rapid and transient rise of cytosolic free calcium which was absent after extracellular calcium was removed, and could be blocked with the vasopressin V1 receptor antagonist, d(CH2)5 Tyr(Me)AVP. Tyrosine 211-214 arginine vasopressin Rattus norvegicus 167-178 1802238-3 1991 Analytical data of the degradation products showed that, in the case of AVP and [Sar7]AVP, there were two major sites of cleavage: Tyr-Phe and Arg-Gly. Tyrosine 131-134 arginine vasopressin Rattus norvegicus 72-75 1802238-3 1991 Analytical data of the degradation products showed that, in the case of AVP and [Sar7]AVP, there were two major sites of cleavage: Tyr-Phe and Arg-Gly. Tyrosine 131-134 arginine vasopressin Rattus norvegicus 86-89 1706722-2 1991 We found that endothelin, angiotensin II, and vasopressin (AVP), peptides that signal via phospholipase C activation, rapidly enhanced tyrosine phosphorylation of proteins of approximate molecular mass 225, 190, 135, 120, and 70 kDa in rat renal mesangial cells. Tyrosine 135-143 arginine vasopressin Rattus norvegicus 46-57 2172766-8 1990 Modifications of the tyrosine residue in position 20 led to the development of two analogues, [D-Tyr20]hNPY and [D-Trp20]hNPY, which show an apparent preference for the vas deferens NPY receptor. Tyrosine 21-29 arginine vasopressin Rattus norvegicus 169-172 2172766-10 1990 This suggests that modifications of tyrosine residues at positions 20 and/or 21 may eventually lead to the development of NPY analogues distinguishing between the most abundant class of sites present in the brain and vas deferens, respectively. Tyrosine 36-44 arginine vasopressin Rattus norvegicus 217-220 2178024-3 1990 The excitatory effect of oxytocin was completely blocked in the presence of the antagonist [d(CH2)5,D-Tyr(OEt)2,Val4,Cit8]vasopressin (5 x 10(-7) M) and a smaller excitation was achieved with equimolar concentration of arginine vasopressin, implicating the involvement of an oxytocin receptor. Tyrosine 102-105 arginine vasopressin Rattus norvegicus 122-133 2529763-6 1989 The second hypothesis was tested by injecting AVP (160 ng/kg) or vehicle intravenously in conscious hypoxia-adapted (4 weeks) or air control rats and measuring ANP in arterial blood and atria, and by testing pretreatment with the V1 receptor antagonist d(CH2)5 Tyr(Me)AVP (130 micrograms/kg) on the AVP-induced increase in plasma ANP. Tyrosine 261-264 arginine vasopressin Rattus norvegicus 46-49 19210425-2 1989 This response was significantly attenuated following perfusion of the intrathecal space with a vasopressin antagonist, d(CH(2))(5)Tyr(Me)AVP. Tyrosine 130-133 arginine vasopressin Rattus norvegicus 95-106 2964381-0 1988 125I-d(CH2)5[Tyr(Me)2, Tyr(NH2)9]AVP: iodination and binding characteristics of a vasopressin receptor ligand. Tyrosine 13-16 arginine vasopressin Rattus norvegicus 82-93 2747038-6 1989 Intravenous preinjection of a vasopressin (AVP) V1 V2 antagonist that has one of the most potent V2 (antidiuretic)-antagonist activities, d(CH2)5-D-Tyr(Et)VAVP, inhibited nearly completely the antidiuretic effects induced by the microinjection of oxotremorine. Tyrosine 148-151 arginine vasopressin Rattus norvegicus 30-41 3226374-6 1988 However, animals treated with the vasopressin antagonist d(CH2)5[Tyr(Me)2]AVP did not show developmental or diuretic deficits. Tyrosine 65-68 arginine vasopressin Rattus norvegicus 34-45 2964381-0 1988 125I-d(CH2)5[Tyr(Me)2, Tyr(NH2)9]AVP: iodination and binding characteristics of a vasopressin receptor ligand. Tyrosine 23-26 arginine vasopressin Rattus norvegicus 82-93 2964381-1 1988 A radioiodinated vasopressin antagonist, d(CH2)5[Tyr(NH2)9]AVP has been prepared. Tyrosine 49-52 arginine vasopressin Rattus norvegicus 17-28 3242998-3 1988 Intravenous vasopressin antagonist, d(CH2)5 Tyr(Me)AVP, significantly attenuated the pressor response and eliminated the bradycardic response to carbachol in LE rats. Tyrosine 44-47 arginine vasopressin Rattus norvegicus 12-23 3676743-6 1987 Application of the VP antagonist d(CH2)5[Tyr(Me)2]VP partly had opposite effects. Tyrosine 41-44 arginine vasopressin Rattus norvegicus 19-21 3676743-6 1987 Application of the VP antagonist d(CH2)5[Tyr(Me)2]VP partly had opposite effects. Tyrosine 41-44 arginine vasopressin Rattus norvegicus 50-52 2959851-9 1987 However, we show that among the monoiodinated peptides some (especially monoiodinated [2-D-Tyrosine]-AVP) retained enough affinity for vasopressin binding sites to suggest that their radioiodinated conterparts would be promising labeled ligands for use in studies in vasopressin receptors. Tyrosine 91-99 arginine vasopressin Rattus norvegicus 135-146 6546972-3 1984 injection of a selective vasopressin vasopressor antagonist, [1-beta-mercapto-beta, beta-cyclopentamethylenepropionic acid-2-(0-methyl)tyrosine]arginine vasopressin (TMe-AVP) were examined in conscious rats under basal conditions and following 48 h of water deprivation. Tyrosine 135-143 arginine vasopressin Rattus norvegicus 25-36 3755870-5 1986 Pretreatment, intrathecally, with 0.5 nmol of the vasopressin antagonist d(CH2)5Me(Tyr)AVP completely prevented the increase in arterial pressure expected after subsequent intrathecal injection of vasopressin. Tyrosine 83-86 arginine vasopressin Rattus norvegicus 50-61 3755870-5 1986 Pretreatment, intrathecally, with 0.5 nmol of the vasopressin antagonist d(CH2)5Me(Tyr)AVP completely prevented the increase in arterial pressure expected after subsequent intrathecal injection of vasopressin. Tyrosine 83-86 arginine vasopressin Rattus norvegicus 197-208 3748327-3 1986 Injected into the preoptic area, arginine vasopressin caused long-lasting hyperthermia of rapid onset that was antagonized by the prior administration of a V1 receptor antagonist, [d(CH2)5 Tyr(Me)AVP]. Tyrosine 189-192 arginine vasopressin Rattus norvegicus 42-53 6206352-5 1984 In conscious rats with established deoxycorticosterone acetate (DOCA)/salt hypertension, d(CH2)5 Tyr (Me) AVP decreased systolic BP after acute administration. Tyrosine 97-100 arginine vasopressin Rattus norvegicus 106-109 7461030-1 1980 A series of 2-O-alkylated tyrosine analogues of lysine-vasopressin and desamino-lysine and arginine-vasopressin were synthesized and tested for antidiuretic activity in the water-loaded anaesthetized rat. Tyrosine 26-34 arginine vasopressin Rattus norvegicus 55-66 18560723-8 2008 The results showed that AVP stimulated DNA synthesis in adult rat CFs, and the effect was abolished by a V1 receptor antagonist, d(CH(2))(5)[Tyr(2)(Me), Arg(8)]-vasopressin (0.1 mumol/L), but not by a V2 receptor antagonist, desglycinamide-[d(CH(2))(5), D-Ile(2), Ile(4), Arg8]-vasopressin (0.1 mumol/L). Tyrosine 141-144 arginine vasopressin Rattus norvegicus 24-27 18581203-3 2008 AVP significantly increased DNA synthesis in adult rat CFs by 73.5 +/- 5.1% (P < or = 0.05), an effect inhibited by V1 receptor antagonist, d(CH(2))(5)[Tyr(2)(Me), Arg(8)]-vasopressin. Tyrosine 155-158 arginine vasopressin Rattus norvegicus 0-3 18581203-3 2008 AVP significantly increased DNA synthesis in adult rat CFs by 73.5 +/- 5.1% (P < or = 0.05), an effect inhibited by V1 receptor antagonist, d(CH(2))(5)[Tyr(2)(Me), Arg(8)]-vasopressin. Tyrosine 155-158 arginine vasopressin Rattus norvegicus 175-186 18560723-8 2008 The results showed that AVP stimulated DNA synthesis in adult rat CFs, and the effect was abolished by a V1 receptor antagonist, d(CH(2))(5)[Tyr(2)(Me), Arg(8)]-vasopressin (0.1 mumol/L), but not by a V2 receptor antagonist, desglycinamide-[d(CH(2))(5), D-Ile(2), Ile(4), Arg8]-vasopressin (0.1 mumol/L). Tyrosine 141-144 arginine vasopressin Rattus norvegicus 161-172 18560723-8 2008 The results showed that AVP stimulated DNA synthesis in adult rat CFs, and the effect was abolished by a V1 receptor antagonist, d(CH(2))(5)[Tyr(2)(Me), Arg(8)]-vasopressin (0.1 mumol/L), but not by a V2 receptor antagonist, desglycinamide-[d(CH(2))(5), D-Ile(2), Ile(4), Arg8]-vasopressin (0.1 mumol/L). Tyrosine 141-144 arginine vasopressin Rattus norvegicus 278-289 16884741-3 2006 Microinjection of AVP into the CdN increased pain threshold in a dose-dependent manner, while local administration of AVP-receptor antagonist-d(CH(2))(5)Tyr(Et)DAVP decreased pain threshold. Tyrosine 153-156 arginine vasopressin Rattus norvegicus 118-121 15993385-6 2005 V1 vasopressin receptor antagonist, d(CH2)5,Tyr(Me)AVP, blocked the suppressive effect caused by cerebral ventricle perfusion with AVP from 64 +/- 4.11% to 83 +/- 1.58%, whereas V2 vasopressin receptor antagonist, d(CH2)5[Ile2, Ile4]AVP, did not block the antinociceptive effect of AVP. Tyrosine 44-47 arginine vasopressin Rattus norvegicus 3-14